Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes

Zhong, Yunshuang; Jia, Chunyan; Zhang, Xinzhong; Liao, Xiali; Yang, Bo; Ye, Cong; Pu, Shengli; Gao, Chuanzhu

doi:10.1016/j.ejmech.2020.112229

Cited by 48 publications

(30 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The oral insertion of platinum(IV) drugs makes it more acceptable among cancer patients because platinum(II) drugs can only be given by injection. The platinum(IV) drugs also avoid disadvantages like irreversible binding to plasma protein, nonspecific distribution in tissue, rapid renal clearance, and instability in blood …”

Section: Extant Therapies For Cancer Treatment and The Role Of Nps In...mentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanoparticle-Based Cancer Treatment: A Review

Bajpai

Tiwary

Sonker

et al. 2021

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The advent and subsequent development of nanotechnology in the past few years have been a boon to the healthcare industry and especially in cancer therapy. Cancer, as it is known, is one of the deadliest maladies that has been plaguing the entire world, and there are several available therapies for the treatment of cancer. In this review, we discuss some of the applications and development in nanoparticle (NP)-based therapies like gene therapy, chemotherapy, etc., and alongside the therapies, there is a detailed discussion about the five deadliest types of cancers. It has been found that NPs have been widely successful compared to the era when the drug was administered alone. However, there are some challenges associated as well. For example, one of the challenges is to make sure that the NP-based drug reaches the target site, and for that, several researchers have been working to design efficient drug-delivery systems, which are discussed in this review. In this review, our aim is to address the utility, developments, and drawbacks of NPs in cancer therapy.

show abstract

Section: Extant Therapies For Cancer Treatment and The Role Of Nps In...mentioning

confidence: 99%

“…The platinum(IV) drugs also avoid disadvantages like irreversible binding to plasma protein, nonspecific distribution in tissue, rapid renal clearance, and instability in blood. 49 3.2. Radiation Therapy.…”

Section: Applications Of Nps In Cancer Treatmentmentioning

confidence: 99%

Recent Advances in Nanoparticle-Based Cancer Treatment: A Review

Bajpai

Tiwary

Sonker

et al. 2021

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Therefore, both these types of "silicon" species can be used as effective drug carriers for platinum-based anticancer drugs. Additionally they can be modified with polyethylene glycol and targeting agents to improve solubility, circulation in blood flow, as well as allow active, and not only passive or triggered delivery [18,19,[22][23][24]. They are also biodegradable and break down into non-toxic orthosilicic acid that is easily excreted [25].…”

Section: Introductionmentioning

confidence: 99%

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview

Piorecka

Kurjata

Stańczyk

2021

IJMS

View full text Add to dashboard Cite

The development in the area of novel anticancer prodrugs (conjugates and complexes) has attracted growing attention from many research groups. The dangerous side effects of currently used anticancer drugs, including cisplatin and other platinum based drugs, as well their systemic toxicity is a driving force for intensive search and presents a safer way in delivery platform of active molecules. Silicon based nanocarriers play an important role in achieving the goal of synthesis of the more effective prodrugs. It is worth to underline that silicon based platform including silica and silsesquioxane nanocarriers offers higher stability, biocompatibility of such the materials and pro-longed release of active platinum drugs. Silicon nanomaterials themselves are well-known for improving drug delivery, being themselves non-toxic, and versatile, and tailored surface chemistry. This review summarizes the current state-of-the-art within constructs of silicon-containing nano-carriers conjugated and complexed with platinum based drugs. Contrary to a number of other reviews, it stresses the role of nano-chemistry as a primary tool in the development of novel prodrugs.

show abstract

“…However, palliative care based on chemotherapy has become a commonly used method for most patients with advanced OSCC, especially those who cannot undergo surgery for systemic diseases or local tumor factors (Vermorken & Specenier, 2010 ). Since its approval in 1979, cisplatin (DDP) has become the first-line treatment for most malignancies, including OSCC (Zhong et al., 2020 ; Meng et al., 2021 ). However, following palliative treatment, the median overall survival time and effectivity rate for patients with relapsed and metastatic OSCC were only 9–11 months and 44%, respectively (Schena et al., 2005 ; Olasz et al., 2010 ).…”

Section: Introductionmentioning

confidence: 99%